These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15276594)
1. Differences in treatment outcome for hepatitis C among ethnic groups. Hepburn MJ; Hepburn LM; Cantu NS; Lapeer MG; Lawitz EJ Am J Med; 2004 Aug; 117(3):163-8. PubMed ID: 15276594 [TBL] [Abstract][Full Text] [Related]
2. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. Satapathy SK; Lingisetty CS; Proper S; Chaudhari S; Williams S J Clin Gastroenterol; 2010 Feb; 44(2):140-5. PubMed ID: 19826275 [TBL] [Abstract][Full Text] [Related]
3. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites. Yu S; Douglass JM; Qualls C; Arora S; Dunkelberg JC Am J Gastroenterol; 2009 Jul; 104(7):1686-92. PubMed ID: 19436272 [TBL] [Abstract][Full Text] [Related]
4. Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. Hu KQ; Freilich B; Brown RS; Brass C; Jacobson IM J Clin Gastroenterol; 2011 Sep; 45(8):720-6. PubMed ID: 21836471 [TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. Rodriguez-Torres M; Jeffers LJ; Sheikh MY; Rossaro L; Ankoma-Sey V; Hamzeh FM; Martin P; N Engl J Med; 2009 Jan; 360(3):257-67. PubMed ID: 19144941 [TBL] [Abstract][Full Text] [Related]
6. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. Srivastava S; Bertagnolli M; Lewis JH J Natl Med Assoc; 2005 Dec; 97(12):1703-7. PubMed ID: 16396063 [TBL] [Abstract][Full Text] [Related]
7. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. McHutchison JG; Poynard T; Pianko S; Gordon SC; Reid AE; Dienstag J; Morgan T; Yao R; Albrecht J Gastroenterology; 2000 Nov; 119(5):1317-23. PubMed ID: 11054390 [TBL] [Abstract][Full Text] [Related]
8. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C; N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352 [TBL] [Abstract][Full Text] [Related]
9. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516 [TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. Muir AJ; Bornstein JD; Killenberg PG; N Engl J Med; 2004 May; 350(22):2265-71. PubMed ID: 15163776 [TBL] [Abstract][Full Text] [Related]
11. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Vutien P; Nguyen NH; Trinh HN; Li J; Garcia RT; Garcia G; Nguyen KK; Nguyen HA; Levitt BS; Keeffe EB; Nguyen MH Am J Gastroenterol; 2010 May; 105(5):1110-5. PubMed ID: 19904247 [TBL] [Abstract][Full Text] [Related]
12. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Missiha S; Heathcote J; Arenovich T; Khan K; Am J Gastroenterol; 2007 Oct; 102(10):2181-8. PubMed ID: 17640318 [TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Shiffman ML; Mihas AA; Millwala F; Sterling RK; Luketic VA; Stravitz RT; Sanyal AJ Am J Gastroenterol; 2007 Apr; 102(4):761-6. PubMed ID: 17319933 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients. Rodríguez-Torres M; Burguera J; Hallman D; Rodríguez-Orengo J; Echeandia M Ann Hepatol; 2012; 11(4):450-63. PubMed ID: 22700626 [TBL] [Abstract][Full Text] [Related]
15. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study. Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754 [TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Berg T; Hoffmann RM; Teuber G; Leifeld L; Lafrenz M; Baumgarten R; Spengler U; Zeuzem S; Pape GR; Hopf U Liver; 2000 Dec; 20(6):427-36. PubMed ID: 11169056 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319 [TBL] [Abstract][Full Text] [Related]
19. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C. Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. Rozenberg L; Haagmans BL; Neumann AU; Chen G; McLaughlin M; Levy-Drummer RS; Masur H; Dewar RL; Ferenci P; Silva M; Viola MS; Polis MA; Kottilil S AIDS; 2009 Nov; 23(18):2439-50. PubMed ID: 19898214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]